04:35 AM EDT, 06/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We revised our target price to USD81 (up from USD64), which implies 19.6x our 2025 EPADS. This is at a discount to its historical forward P/E average of 30x-32x, justified in our view to reflect the increasing concerns about its long-term competitive edge, but above the peer average of 12.9x to reflect NOVO's higher growth and margins. NOVO is advancing subcutaneous and oral Amycretin to a phase 3 study in weight management, providing some positive updates on the company after a series of setbacks, in our view. NOVO is now planning to initiate a phase 3 program with Amycretin for adults with overweight or obesity during Q1 2026. Amycretin is NOVO's experimental obesity drug, which has shown encouraging data so far, in contrast to its other experimental obesity drug, CagriSema. Data readouts from Amycretin's late-stage trials will be crucial in our view, especially in light of the repeated disappointments surrounding CagriSema's results.